Introduction
============

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of the synovial joints resulting in joint destruction, polyarthritis and functional disability. This inflammatory condition affects approximately 1% of the Caucasian population, making it a significant cause of comorbidity and mortality \[[@B1]\].

In recent years, the use of tumor necrosis factor inhibitors (TNFi) has resulted in an improvement in the treatment of RA patients by reducing both inflammation and joint damage \[[@B2]-[@B4]\], and their clinical use has become widespread. However, a percentage of patients do not respond adequately to this therapy; therefore, the current use of these agents is based on a trial-and-error approach \[[@B5],[@B6]\]. Given the adverse effects and the high cost of this type of therapy, the establishment of pharmacogenetic markers to predict the response to TNFi treatment is a highly desirable goal.

Recently, researchers in pharmacogenetic studies have reported several genetic variants associated with clinical response to treatment with TNFi \[[@B7]-[@B11]\]. However, to date, only the *PTPRC* and *PDE3A-SLCO1C1 loci* have been associated in more than a single study \[[@B12]-[@B14]\].

In 2011, Plant *et al*. \[[@B8]\] performed a genome-wide association study (GWAS) in a large number of RA patients from the United Kingdom treated with TNFi. These investigators used a three-stage study design. The meta-analysis combining stages 1, 2 and 3 cohorts yielded four single-nucleotide polymorphisms (SNPs) putatively associated with the TNFi response at 6 months, although these associations did not reach the GWAS significance level. Two of the genetic variants mapped within genes, PDZ domain-containing 2 (*PDZD2*) and eyes absent homolog 4 (*EYA4*), and two polymorphisms mapped to intergenic regions on chromosomes 1 and 12. However, two subsequent GWASs conducted in European RA patients, whose treatment response was evaluated at 14 weeks, failed to replicate association with any of the four *loci*\[[@B9],[@B10]\].

The aim of our study was to assess the role of the four genetic variants identified by Plant *et al.*\[[@B8]\] with regard to their association with response to TNFi using a large number of RA Spanish patients, as well as to conduct a meta-analysis including previous data.

Methods
=======

Patients
--------

Two sets of RA patients of Spanish ancestry treated with TNFi (infliximab, adalimumab and etanercept) were included in the study. Collection 1 comprised 438 patients, and collection 2 included 196 patients. All patients were classified according to the 1987 American Rheumatism Association criteria \[[@B15]\]. Informed written consent from all participants and approval from the local ethical committees (Comité Ético de Investigación Clínica de Galicia and Comité de Bioética del Consejo Superior de Investigaciones Científicas) were obtained in accordance with the tenets of the Declaration of Helsinki. The characteristics of the patients enrolled in this study are shown in Table [1](#T1){ref-type="table"}.

###### 

**Baseline characteristics of the rheumatoid arthritis patients**^**a**^

  **Baseline characteristics**                   **Collection 1 (*N*= 438)**   **Collection 2 (*N*= 196)**
  ---------------------------------------------- ----------------------------- -----------------------------
  Age, mean ± SD years                           61.0 ± 12.04                  56.3 ± 14.77
  Age at diagnosis, mean ± SD years              44.95 ± 13.03                 42.99 ± 13.69
  Females, *n* (%)                               365 (83.3)                    160 (81.6)
  Disease duration, mean ± SD years              16.45 ± 8.34                  12.93 ± 8.47
  Rheumatoid factor--positive, *n* (%)           340 (77.8)                    141 (71.94)
  Anti-CCP-positive, *n* (%)                     250 (69.6)^b^                 125 (73.1)^c^
  Smoking status, *n* (%)                                                       
  Ever-smoker                                    51 (16.0)^b^                  20 (13.9)^c^
  Never-smoker                                   267 (84.0)^b^                 124 (86.1)^c^
  Health status, mean ± SD                                                      
  DAS28 at baseline                              5.86 ± 1.12                   5.36 ± 1.13
  Treatment, *n* (%)                                                            
  Concurrent DMARDs                              252 (92.6)^b^                 159 (81.1)
  Previous biologic agents                       0 (0)                         14 (10.2)^c^
  Anti-TNF drugs, *n* (%)                                                       
  Infliximab                                     245 (55.9)                    62 (31.6)
  Etanercept                                     113 (25.8)                    21 (10.7)
  Adalimumab                                     80 (18.3)                     113 (57.7)
  EULAR-defined response at 6 months, *n* (%)                                   
  Responders                                     337 (80.4)                    167 (85.2)
  Nonresponders                                  82 (19.6)                     29 (14.8)
  EULAR-defined response at 12 months, *n* (%)                                  
  Responders                                     259 (82.5)                    118 (88.1)
  Nonresponders                                  55 (17.5)                     16 (11.9)

^a^Anti-CCP, Anti--cyclic citrullinated peptide antibody; DAS28, Disease Activity Score in 28 joints; DMARD, Disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; TNF, Tumor necrosis factor. ^b^Data are from \<85% of the patients: 359 for anti-CCP status, 318 for smoking status and 272 for concurrent DMARD treatment. ^c^Data are from \<70% of the patients: 171 for anti-CCP status, 144 for smoking status and 137 for previous biologic agent treatment.

Treatment outcomes
------------------

The Disease Activity Score in 28 joints (DAS28) was measured at baseline and at 6 and 12 months after the first TNFi infusion. Two scales were considered to assess the efficacy of the TNFi therapy. First, the absolute change in DAS28 (∆DAS28 = DAS28~end~ -- DAS28~baseline~) at 6 and 12 months of follow-up. Second, patients were classified as responders (good and moderate) or nonresponders at 6 and 12 months according to the European League Against Rheumatism (EULAR) response criteria \[[@B16]\].

Genotyping
----------

Genomic DNA was extracted from peripheral white blood cells or saliva using standard procedures. Four SNPs---rs1532269 and rs17301249, intronic polymorphisms mapped within *PDZD2* and *EYA4*, respectively, and rs12081765 and rs7305646 located at intergenic regions on chromosomes 1 and 12, respectively---were genotyped using a single-base extension technology (SNaPshot Multiplex Kit; Applied Biosystems, Foster City, CA, USA) in a multiplex PCR experiment (KAPA2G Fast HotStart; Kapa Biosystems, Wilmington, MA, USA) in collection 1 and using TaqMan allelic discrimination assays on a 7900HT Fast Real-Time PCR System, both purchased from Applied Biosystems, in collection 2. A deviation from Hardy--Weinberg equilibrium (HWE) was detected for the rs1532269 polymorphism in collection 2, so that SNP was genotyped in this sample set using the same methodology used for collection 1.

Statistical analysis
--------------------

Power calculations were performed using Quanto version 1.2.4 software \[[@B17]\]. All SNPs were tested for deviations from HWE. The association between SNPs and responses to TNFi was evaluated in two ways. In the first method, linear regression analysis using ∆DAS28 as the continuous dependent variable was performed under an additive genetic model using Plink version 1.07 statistical software \[[@B18]\]. A *t*-test was used to identify polymorphisms associated with the response. In the second method, genotype and allele frequencies between EULAR-defined responder and nonresponder patients were compared. Plink was used to create 2 × 2 or 2 × 3 contingency tables and to perform a *χ*^2^ test and/or Fisher's exact test. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated according to Woolf's method. Because our present study is a replication study, no correction was applied to the obtained *P*-values when TNFi response was evaluated at 6 months. In the analyses involving the TNFi efficacy at 12 months, however, *P*-values were corrected by using the Benjamini--Hochberg step-up procedure to control for false discovery rates (FDRs) in multiple testing \[[@B19]\]. The results were considered statistically significant when *P*-values were lower than 0.05.

Clinical variables previously identified as being independent predictors of efficacy of TNFi, including age, gender, smoking status, rheumatoid factor status, anti--cyclic citrullinated peptide antibody (anti-CCP) status, DAS28 at baseline, concurrent and previous treatment and TNFi, were assessed for association with treatment response in a multivariate regression analysis using *STATISTICA* version 7.0 software (StatSoft, Tulsa, OK, USA) and Plink software in collections 1 and 2, respectively. Only baseline DAS28, gender and TNFi were associated with the efficacy of the therapy. Accordingly, analyses were adjusted for these three variables.

The analysis of the combined data from our study and the previous reports \[[@B8]-[@B10]\] was performed using Plink. Heterogeneity between studies was assessed using Cochran's *Q* and *I*^2^ statistics \[[@B20]\]. Pooled analyses were performed by using the Mantel--Haenszel test under the fixed-effects model or the DerSimonian--Laird test under the random-effects model when heterogeneity was detected. The results were considered to be statistically significant when *P*-values were lower than 5 × 10^5.00E−08^.

Results
=======

All of the four studied polymorphisms conformed to HWE expectations (*P* \> 0.01). The genotyping success rate was higher than 95%.

Replication study
-----------------

First, we analyzed the association between the four tested polymorphisms and the efficacy of the TNFi therapy in the 438 RA patients of Spanish Caucasian origin in collection 1. As shown in Table [2](#T2){ref-type="table"}, in the linear regression analysis using ∆DAS28, none of the analyzed genetic variants were associated with the clinical response at 6 months (*P* = 0.570, *P* = 0.831, *P* = 0.181 and *P* = 0.244 for rs12081765, rs1532269, rs17301249 and rs7305646, respectively) or at 12 months (*P* = 0.716, *P* = 0.647, *P* = 0.416 and *P* = 0.182 for rs12081765, rs1532269, rs17301249 and rs7305646, respectively). Likewise, when allele frequencies were compared between responder and nonresponder patients, no association with the EULAR-defined response at 6 or 12 months was observed for any of the analyzed polymorphisms (see Additional file [1](#S1){ref-type="supplementary-material"}: Tables S1 and S2).

###### 

**Association of the four single-nucleotide polymorphisms with changes in Disease Activity Score in 28 joints at 6 and 12 months in Spanish rheumatoid arthritis patients**^**a**^

                                  **6 months**   **12 months**                                                                              
  ------------ ------------ ----- -------------- --------------- -------- ------- ------- -------- ------- ------- -------- ------- ------- --------
  rs12081765   Intergenic   A/G   0.415          0.570           0.055    0.458   0.995   0.001    0.411   0.716   0.043    0.408   0.677   0.062
  rs1532269    *PDZ2D*      C/G   0.375          0.831           0.020    0.418   0.830   0.022    0.400   0.647   0.051    0.420   0.022   0.335
  rs17301249   *EYA4*       C/G   0.121          0.181           −0.190   0.132   0.458   0.120    0.131   0.416   −0.137   0.154   0.529   0.135
  rs7305646    Intergenic   T/C   0.474          0.244           −0.117   0.487   0.661   −0.049   0.486   0.182   −0.161   0.473   0.554   −0.093

^a^1, Minor allele, 2, Major allele; MAF, Minor allele frequency; SNP, Single-nucleotide polymorphism. ^b^Adjusted for gender, anti--tumor necrosis factor treatment and Disease Activity Score in 28 joints at baseline.

In the subsequent analysis in collection 2, none of the tested polymorphisms showed an association with ∆DAS28 at 6 months (Table [2](#T2){ref-type="table"}) (*P* = 0.995, *P* = 0.830, *P* = 0.458 and *P* = 0.661 for rs12081765, rs1532269, rs17301249 and rs7305646, respectively) or in the stratified analysis according to the EULAR-defined response (see Additional file [1](#S1){ref-type="supplementary-material"}: Table S1). When TNFi efficacy was evaluated at 12 months, the rs1532269 polymorphism showed an association with ∆DAS28 at that time point (Table [2](#T2){ref-type="table"}) (*P* = 0.022, β = 0.335); however, statistical significance was lost after correction using the Benjamini--Hochberg step-up procedure for FDR (*P*~FDR~ = 0.087). No association of this SNP with the EULAR-defined response at the 12-month time point was observed (see Additional file [1](#S1){ref-type="supplementary-material"}: Table S2).

No heterogeneity was observed (*P* \> 0.1 by Cochran's *Q*-statistic) before we performed the meta-analysis of the two Spanish collections. No association between rs12081765, rs1532269, rs17301249 and rs7305646 and the efficacy of the TNFi therapy was evident in this pooled analysis for any of the outcomes considered as measured by ∆DAS28 (Table [3](#T3){ref-type="table"}) and EULAR-defined response (see Additional file [1](#S1){ref-type="supplementary-material"}: Table S3).

###### 

Pooled analysis of the tested polymorphisms in the two Spanish cohorts

                            **Meta-analysis**                     
  ------------ ------------ ------------------- -------- -------- --------
  rs12081765   Intergenic   0.677               0.029    0.586    0.050
  rs1532269    *PDZ2D*      0.762               0.021    0.074    0.158
  rs17301249   *EYA4*       0.607               −0.055   0.8041   −0.033
  rs7305646    Intergenic   0.246               −0.086   0.1549   −0.136

Meta-analysis of all available studies
--------------------------------------

We combined our data with the results of three previous studies in order to assess the global status of the four polymorphisms \[[@B8]-[@B10]\]. Results corresponding to ∆DAS28 at 14 weeks from two of the studies \[[@B9],[@B10]\] were combined with results at 24 weeks from the other two studies (\[[@B8]\] and present meta-analysis). A total of 2,998 RA patients were included in the meta-analysis, which had \>90% power to detect a difference of ≥0.6 units in ∆DAS28 at the GWAS significance threshold (*P* ≤ 5.0E-08) for allele frequencies ≥10%. Only one of the polymorphisms, rs1532269, showed a suggestive association (fixed-effects model: *P* = 0.0033, β = 0.107) (Table [4](#T4){ref-type="table"}), although it did not reach the GWAS significance level. The other three were not associated with ∆DAS28 at 3 to 6 months (random-effects model: *P* = 0.102, β = 0.068; *P* = 0.063, β = −0.138; and *P* = 0.085, β = −0.095, for rs12081765, rs17301249 and rs7305646, respectively) (Table [4](#T4){ref-type="table"}). When data derived from the four studies were pooled, heterogeneity for the rs12081765, rs17301249 and rs7305646 variants was evident (Cochran's *Q*-statistic *P* \< 0.05, *I*^2^ \> 40%).

###### 

**Meta-analysis of association of four single-nucleotide polymorphisms with changes in Disease Activity Score in 28 joints in all available studies**^**a**^

                                                                           **rs12081765**              **rs1532269**           **rs17301249**           **rs7305646**                                          
  ------------------------------------- ---------------------------------- ---------------- ---------- --------------- ------- ---------------- ------- --------------- ---------- -------- ------- ---------- --------
  Plant *et al*. \[[@B8]\]              Cohort 1 (*n* = 566)               0.43             7.52E-04   0.29            0.37    7.11E-04         0.3     0.20            3.37E-04   −0.38    0.47    9.16E-04   −0.28
  Cohort 2 (*n* = 379)                  0.46                               0.062            0.19       0.35            0.079   0.19             0.19    0.045           −0.24      0.49     0.049   −0.21      
  Cohort 3 (*n* = 341)                  0.47                               0.712            0.04       0.34            0.701   0.04             0.19    0.261           −0.14      0.50     0.292   −0.11      
  Krintel *et al*. \[[@B9]\]            Copenhagen cohort (*n* = 196)      0.47             0.940      0.008           0.36    0.360            0.116   0.18            0.570      0.89     0.48    0.740      0.042
  Umicevic Mirkov *et al*. \[[@B10]\]   Dutch stage 1 cohort (*n* = 882)   0.39             0.730      −0.024          0.43    0.920            0.051   0.18            0.360      −0.05    0.50    0.390      0.05
  Present study                         Collection 1 (*n* = 438)           0.42             0.570      0.055           0.38    0.831            0.020   0.12            0.181      −0.190   0.47    0.244      −0.117
  Collection 2 (*n* = 196)              0.46                               0.995            0.001      0.42            0.830   0.022            0.13    0.458           0.120      0.49     0.661   −0.049     
  Meta-analysis                         *N* = 2,998                                         0.102      0.068                   0.0033           0.107                   0.063      −0.138           0.085      −0.095

^**a**^MAF, Minor allele frequency.

Discussion
==========

Our results make it unlikely that any of the four polymorphisms identified by Plant *et al*. could be used as genetic predictors of TNFi treatment outcomes, because they were not associated in our large Spanish RA study. This lack of association represents a very relevant finding because, to the best of our knowledge, our present study is the first in which the association of these SNPs was analyzed with the same treatment outcomes used for their identification. In addition, the combined analysis with the three previous studies included in our meta-analysis \[[@B8]-[@B10]\] showed only a suggestive association of one of the four polymorphisms (even weaker than that reported in the study by Plant *et al*. \[[@B8]\]). These findings seem to exclude effects of sufficient magnitude to be useful in predicting response to treatment.

The lack of replication in our study could be ascribed to multiple differences between studies. It is commonly impossible to identify one of them as being more relevant than the others. Genetic differences between populations are an unlikely explanation of the results, given that the allele frequencies of the four tested polymorphisms were very similar between studies. Clinical differences between the patients with RA included in the different reports are possible and difficult to exclude. In this regard, it has already been mentioned that Plant *et al*. \[[@B8]\] evaluated the response to TNFi at 6 months, whereas the two subsequent studies used the response at 14 weeks. However, this difference does not apply to our study in which evaluation at 6 months evidenced negative results. A common cause of discrepant results is the overestimation of the true effect in the discovery study. This phenomenon has been characterized as the "winner's curse," and it has been very prevalent in genetic association studies \[[@B21]\]. It should be noted that the four SNPs studied by Plant *et al*. \[[@B8]\] showed the highest effects in the discovery cohort (which was the only one with a clear association between these four polymorphisms and the clinical response), whereas the three replication studies showed lower effect sizes (β-values less different from zero), thus supporting this possibility. Indeed, significant heterogeneity between studies was observed in the meta-analysis of three of the four analyzed genetic variants. Interestingly, this heterogeneity disappeared when the discovery cohort of Plant *et al*. was removed \[[@B8]\]. Therefore, variables other than the presence of the four SNPs considered herein could have influenced the efficacy of TNFi in this cohort, accounting for its singularity.

Other GWASs of responses to TNFi treatment in RA have been published \[[@B7],[@B9]-[@B11]\]. This approach represents an important step forward in the understanding of the influence of genetic variability on the efficacy of this therapy. Only one of the observed associations has been found to reach the GWAS statistical significance level, however, and only after combination with data derived from replication studies \[[@B12]\]. This highlights the important role of validation studies in determining the status of the remaining GWAS findings. It is to be expected that these combined efforts will produce useful insights.

Conclusions
===========

The association of four polymorphisms (rs12081765, rs1532269, rs17301249 and rs7305646) previously identified as being associated with TNFi treatment response was not confirmed in the present study. Our results indicate that these four genetic variants are not useful predictors of response to TNFi in patients with RA.
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